The Pre-Market Environment (EpM), BME’s acceleration program for integrating companies into financial markets, welcomes three new companies: KeyZell, Pharmamel, and OpenWebinars. With these additions, there are now 25 companies currently part of this BME initiative. Since its inception, 41 companies have participated in the Pre-Market Environment, seven of which have already transitioned to the market, specifically to BME Growth.
Pharmamel is a biotechnology company that emerged as a spin-off from the University of Granada. As a result of technology transfer and investment in R&D&I, the company has developed and patented a new intravenous melatonin drug to treat sepsis (the leading cause of hospital death worldwide). After successfully testing the new drug in two Phase II clinical trials and demonstrating its effectiveness and efficacy, the company is now tackling the development and completion of the Phase III clinical trial for its subsequent commercialization and licensing.
With these new additions, the Pre-Market Environment continues preparing companies for their future entry into financial markets through its training and development program. The call for companies and investors remains open and ongoing.
Source: bolsamania.com